DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

04 янв 2024 21:46:36 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

03 янв 2024 15:25:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

03 янв 2024 05:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at November Investor Conferences

07 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

30 окт 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at October Investor Conferences

28 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

20 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 сен 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

03 авг 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Healthcare Conference

01 июн 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

25 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

17 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

11 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

03 май 2023 06:35:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

02 май 2023 15:46:03 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

23 мар 2023 06:30:17 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

20 мар 2023 06:30:24 Источник Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

02 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire